OncoTherapy Science, Inc.
OncoTherapy Science, Inc. (4564.T) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for OncoTherapy Science, Inc. (4564.T), featuring income statements, balance sheets, and cash flow data.
OncoTherapy Science, Inc. (4564.T) Income Statement & Financial Overview
Analyze OncoTherapy Science, Inc.’s 4564.T earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $186.75M | $338.00M | $125.00M | $100.00M |
| Cost of Revenue | $175.68M | $297.58M | $152.41M | $281.00M |
| Gross Profit | $11.07M | $40.42M | -$28.04M | -$181.00M |
| Gross Profit Ratio | $0.06 | $0.12 | -$0.22 | -$1.81 |
| R&D Expenses | $128.86M | $99.88M | $118.32M | $0.00 |
| SG&A Expenses | $0.00 | $108.00M | $95.00M | $109.00M |
| Operating Expenses | $128.86M | $207.72M | $95.00M | $109.00M |
| Total Costs & Expenses | $304.54M | $505.00M | $366.00M | $390.00M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $327000.00 | $0.00 | $0.00 | $327000.00 |
| Depreciation & Amortization | $0.00 | $167.00M | $241.00M | $290.00M |
| EBITDA | -$115.25M | -$170.66M | -$242.65M | -$11.42M |
| EBITDA Ratio | -$0.62 | -$0.50 | -$1.94 | -$0.11 |
| Operating Income | -$117.79M | -$167.00M | -$241.00M | -$290.00M |
| Operating Income Ratio | -$0.63 | -$0.49 | -$1.93 | -$2.90 |
| Other Income/Expenses (Net) | $20.28M | -$5.00M | -$1.00M | -$12.00M |
| Income Before Tax | -$97.51M | -$172.00M | -$242.00M | -$302.00M |
| Income Before Tax Ratio | -$0.52 | -$0.51 | -$1.94 | -$3.02 |
| Income Tax Expense | $540000.00 | $540000.00 | $1.00M | $0.00 |
| Net Income | -$98.05M | -$172.00M | -$243.00M | -$302.00M |
| Net Income Ratio | -$0.53 | -$0.51 | -$1.94 | -$3.02 |
| EPS | -$0.36 | -$0.63 | -$0.91 | -$1.30 |
| Diluted EPS | -$0.36 | -$0.63 | -$0.91 | -$1.30 |
| Weighted Avg Shares Outstanding | $271.45M | $271.72M | $268.45M | $232.96M |
| Weighted Avg Shares Outstanding (Diluted) | $271.45M | $271.72M | $268.45M | $232.96M |
Over the last four quarters, OncoTherapy Science, Inc.'s revenue moved from $100.00M in Q1 2024 to $186.75M in Q4 2024. Operating income in Q4 2024 was -$117.79M, with a strong operating margin of -63%. Despite fluctuations in R&D and SG&A expenses, EBITDA for OncoTherapy Science, Inc. remained robust at -$115.25M, reflecting operational efficiency. Net income rose to -$98.05M, with an EPS of -$0.36. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan